Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
AstraZeneca PLC - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AZN
New York
2834
www.astrazeneca.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for AstraZeneca PLC
3 British Stocks Trading Up To 43% Below Cash Flow Value
- Nov 21st, 2026 8:09 am
AstraZeneca leads European big pharma on growth, pipeline depth
- Nov 20th, 2026 9:25 am
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
- Nov 20th, 2026 8:13 am
Oncology Clinical Trials - Global Strategic Business Report 2026: Secure Share of a $6 Billion Revenue Surge by 2032 as AbbVie, AstraZeneca, ICON, Merck, and Roche Accelerate AI-Led Trials
- Nov 20th, 2026 8:01 am
European shares tumble again as Anthropic debut fails to halt tech rout
- Nov 20th, 2026 1:36 am
Why AstraZeneca Could Make Sense Through ETFs Now
- Nov 19th, 2026 9:09 am
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
- Nov 19th, 2026 8:10 am
Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Form New Collaboration with AstraZeneca to Advance Drug Development in Lupus
- Nov 19th, 2026 6:33 am
Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers
- Nov 19th, 2026 5:00 am
AstraZeneca gets Jefferies backing as broker sees $80bn sales target within reach
- Nov 18th, 2026 8:30 am
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
- Nov 18th, 2026 7:21 am
The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
- Nov 18th, 2026 3:43 am
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
- Nov 17th, 2026 7:58 am
Summit Therapeutics (SMMT) Stock Sees Modest Fair Value Cut As Analysts Weigh Trial Risks
- Nov 17th, 2026 4:14 am
AstraZeneca Bet $2 Billion on Summit’s Cancer Drug. The FDA Just Said Not Yet.
- Nov 16th, 2026 9:37 am
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading
- Nov 16th, 2026 9:21 am
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
- Nov 16th, 2026 9:02 am
FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug
- Nov 16th, 2026 7:31 am
Scroll